Retinal Degeneration Clinical Trials

10 recruiting

Retinal Degeneration Trials at a Glance

11 actively recruiting trials for retinal degeneration are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Bethesda, Ann Arbor, and Jacksonville. Lead sponsors running retinal degeneration studies include National Eye Institute (NEI), PYC Therapeutics, and Incepta Pharmaceuticals Ltd.

Browse retinal degeneration trials by phase

Treatments under study

About Retinal Degeneration Clinical Trials

Looking for clinical trials for Retinal Degeneration? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinal Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinal Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting

Rod and Cone Mediated Function in Retinal Disease

Stargardt's DiseaseRetinal DegenerationRetinitis Pigmentosa
National Eye Institute (NEI)500 enrolled1 locationNCT02617966
Recruiting
Phase 1Phase 2

Oral Metformin for Treatment of ABCA4 Retinopathy

Retinal DegenerationRetinal DystrophyStargardt Disease+1 more
National Eye Institute (NEI)56 enrolled2 locationsNCT04545736
Recruiting

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Retinitis PigmentosaInherited Retinal Degeneration
Jaeb Center for Health Research1,500 enrolled36 locationsNCT05589714
Recruiting
Phase 2

SGLT2 Inhibitors in Geographic Atrophy

Retinal Degeneration
Washington University School of Medicine70 enrolled1 locationNCT07174687
Recruiting
Phase 1Phase 2

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Not Applicable

High Resolution, High-speed Multimodal Ophthalmic Imaging

HypertensionStrokeDiabetes+12 more
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts1,200 enrolled1 locationNCT04129021
Recruiting
Phase 3

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Retinal DegenerationMacular DegenerationDiabetic Retinopathy+3 more
Incepta Pharmaceuticals Ltd70 enrolled1 locationNCT06305416
Recruiting

Adaptive Optics Imaging of Outer Retinal Diseases

Age-Related Macular DegenerationRetinal DegenerationRetinitis Pigmentosa+4 more
Food and Drug Administration (FDA)100 enrolled2 locationsNCT05355415
Recruiting
Phase 1

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

Retinal DegenerationRetinal DiseaseEye Diseases+2 more
PYC Therapeutics12 enrolled5 locationsNCT06455826
Recruiting
Phase 1Phase 2

Minocycline for Chronic Autoimmune Uveitis

MinocyclineUveitisRetinal Degeneration
Sun Yat-sen University10 enrolled1 locationNCT05474729